Gastric Neuroendocrine Tumors According to the 2019 World Health Organization Grading System: A Single-Center, Retrospective Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Although gastric neuroendocrine tumors (NETs) are uncommon neoplasms, their prevalence is increasing. The clinical importance of the World Health Organization (WHO) classification of gastric NETs, compared with NETs in other organs, has been underestimated. This study aimed to systematically evaluate the clinical and pathologic characteristics of gastric NETs based on the 2019 WHO classification and to assess the survival outcomes of patients from a single-center with a long-term follow-up. Methods: The medical records of 427 patients with gastric NETs who underwent endoscopic or surgical resection between January 2000 and March 2020 were retrospectively reviewed. All specimens were reclassified according to the 2019 WHO classification. The clinicopathologic characteristics, treatment, and oncologic outcomes of 139 gastric NETs were analyzed. Results: The patients’ median age was 53.0 years (interquartile range [IQR], 46.0 to 63.0 years). The median follow-up period was 36.0 months (IQR, 15.0 to 63.0 months). Of the patients, 92, 44, and 3 had grades 1, 2, and 3 NETs, respectively. The mean tumor size significantly increased as the tumor grade increased (p=0.025). Patients with grades 2 and 3 gastric NETs more frequently had lymphovascular invasion (29.8% vs 10.9%, p=0.005) and deeper tissue invasion (8.5% vs 0%, p=0.012) than those with grade 1 tumors. The overall disease-specific survival rate was 100%. Two patients with grades 2-3 gastric NETs experienced extragastric recurrence. Conclusions: Although gastric NETs have an excellent prognosis, grade 2 or grade 3 gastric NETs are associated with a larger size, deeper invasion, and extragastric recurrence, which require active treatment.
Abstract
Background/Aims: Although gastric neuroendocrine tumors (NETs) are uncommon neoplasms, their prevalence is increasing. The clinical importance of the World Health Organization (WHO) classification of gastric NETs, compared with NETs in other organs, has been underestimated. This study aimed to systematically evaluate the clinical and pathologic characteristics of gastric NETs based on the 2019 WHO classification and to assess the survival outcomes of patients from a single-center with a long-term follow-up. Methods: The medical records of 427 patients with gastric NETs who underwent endoscopic or surgical resection between January 2000 and March 2020 were retrospectively reviewed. All specimens were reclassified according to the 2019 WHO classification. The clinicopathologic characteristics, treatment, and oncologic outcomes of 139 gastric NETs were analyzed. Results: The patients’ median age was 53.0 years (interquartile range [IQR], 46.0 to 63.0 years). The median follow-up period was 36.0 months (IQR, 15.0 to 63.0 months). Of the patients, 92, 44, and 3 had grades 1, 2, and 3 NETs, respectively. The mean tumor size significantly increased as the tumor grade increased (p=0.025). Patients with grades 2 and 3 gastric NETs more frequently had lymphovascular invasion (29.8% vs 10.9%, p=0.005) and deeper tissue invasion (8.5% vs 0%, p=0.012) than those with grade 1 tumors. The overall disease-specific survival rate was 100%. Two patients with grades 2-3 gastric NETs experienced extragastric recurrence. Conclusions: Although gastric NETs have an excellent prognosis, grade 2 or grade 3 gastric NETs are associated with a larger size, deeper invasion, and extragastric recurrence, which require active treatment.
참고문헌 (43)
- Oberndorfer S, "Karzinoide tumoren des dunndarms", Frankfurt Z Path, 1, pp.426~432 (1907)
- Lawrence B, "A clinical perspective on gastric neuroendocrine neoplasia", Curr Gastroenterol Rep, 13, pp.101~109 (2011)
- Modlin IM, "Gastrointestinal carcinoids : the evolution of diagnostic strategies", J Clin Gastroenterol, 40, pp.572~582 (2006)
- Basuroy R, "Review article : the investigation and management of gastric neuroendocrine tumours", Aliment Pharmacol Ther, 39, pp.1071~1084 (2014)
- Niederle MB, "Gastroenteropancreatic neuroendocrine tumours : the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification : an analysis based on prospectively collected parameters", Endocr Relat Cancer, 17, pp.909~918 (2010)
- Klöppel G, "The gastroenteropancreatic neuroendocrine cell system and its tumors : the WHO classification", Ann N Y Acad Sci, 1014, pp.13~27 (2004)
- Sato Y, "Management of gastric and duodenal neuroendocrine tumors", World J Gastroenterol, 22, pp.6817~6828 (2016)
- Rindi G, "Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma : a clinicopathologic study", Gastroenterology, 104, pp.994~1006 (1993)
- La Rosa S, "Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms", Hum Pathol, 42, pp.1373~1384 (2011)
- Christopoulos C, "Gastric neuroendocrine tumors : biology and management", Ann Gastroenterol, 18, pp.127~140 (2005)
- Nagtegaal ID, "The 2019 WHO classification of tumours of the digestive system", Histopathology, 76, pp.182~188 (2020)
- Ji-Yeon Mun, "A 13-year experience with gastric neuroendocrine tumors: A single institute study", 대한종양외과학회지, 14(1), pp.8~14 (2018), 대한종양외과학회[DOI]
- Yang Z, "Gastric neuroendocrine tumors(G-Nets) : incidence, prognosis and recent trend toward improved survival", Cell Physiol Biochem, 45, pp.389~396 (2018)
- Roberto GA, "Gastric neuroendocrine tumor : a practical literature review", World J Gastrointest Oncol, 12, pp.850~856 (2020)
- Kimura K, "An endoscopic recognition of the atrophic border and its significance in chronic gastritis", Endoscopy, 1, pp.87~97 (1969)
- Warren S, "Multiple primary malignant tumors : a survey of the literature and a statistical study", Am J Cancer, 16, pp.1358~1414 (1932)
- Cockburn AN, "Neuroendocrine proliferations of the stomach : a pragmatic approach for the perplexed pathologist", Adv Anat Pathol, 20, pp.148~157 (2013)
- Amin MB, "AJCC cancer staging manual" (2018), Springer International Publishing
- Hallet J, "Exploring the rising incidence of neuroendocrine tumors : a population-based analysis of epidemiology, metastatic presentation, and outcomes", Cancer, 121, pp.589~597 (2015)
- Yao JC, "One hundred years after"carcinoid" : epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States", J Clin Oncol, 26, pp.3063~3072 (2008)
- Dasari A, "Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States", JAMA Oncol, 3, pp.1335~1342 (2017)
- Frilling A, "Neuroendocrine tumor disease : an evolving landscape", Endocr Relat Cancer, 19, pp.R163~R185 (2012)
- Cives M, "Gastroenteropancreatic neuroendocrine tumors", CA Cancer J Clin, 68, pp.471~487 (2018)
- Dacha S, "Hypergastrinemia", Gastroenterol Rep(Oxf), 3, pp.201~208 (2015)
- Lundell L, "Systematic review : the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology", Aliment Pharmacol Ther, 42, pp.649~663 (2015)
- Butler OL, "Frequency and causes of false-positive elevated plasma concentrations of fasting gut hormones in a specialist neuroendocrine tumor center", Front Endocrinol(Lausanne), 11, pp.606264~ (2020)
- Rindi G, "The 2010 WHO classification of digestive neuroendocrine neoplasms : a critical appraisal four years after its introduction", Endocr Pathol, 25, pp.186~192 (2014)
- Garcia-Carbonero R, "Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors(GEP-NETs) : results from the National Cancer Registry of Spain(RGETNE)", Ann Oncol, 21, pp.1794~1803 (2010)
- Gluckman CR, "Gastric neuroendocrine tumors(carcinoids)", Curr Gastroenterol Rep, 21, pp.13~ (2019)
- Chung CS, "Clinical features and outcomes of gastric neuroendocrine tumors after endoscopic diagnosis and treatment: a Digestive Endoscopy Society of Tawian (DEST)", Medicine(Baltimore), 97, pp.e12101~ (2018)
- Pape UF, "Management of followup of neuroendocrine neoplasias", Best Pract Res Clin Endocrinol Metab, 30, pp.129~140 (2016)
- Kulke MH, "Neuroendocrine tumors, version 1. 2015", J Natl Compr Canc Netw, 13, pp.78~108 (2015)
- Delle Fave G, "ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms", Neuroendocrinology, 95, pp.74~87 (2012)
- Jun Liong Chin, "Diagnosis and Management of Upper Gastrointestinal Neuroendocrine Tumors", Clinical Endoscopy, 50(6), pp.520~529 (2017), 대한소화기내시경학회
- Bosman FT, "WHO classification of tumours of the digestive system", World Health Organization, ~ (2010)
- Lloyd RV, "WHO classification of tumours of endocrine organs", International Agency for Research on Cancer, ~ (2017)
- Sato Y, "Management and clinical outcomes of type I gastric carcinoid patients : retrospective, multicenter study in Japan", Dig Endosc, 26, pp.377~384 (2014)
- Merola E, "Type I gastric carcinoids : a prospective study on endoscopic management and recurrence rate", Neuroendocrinology, 95, pp.207~213 (2012)
- Uygun A, "Long-term results of endoscopic resection for type I gastric neuroendocrine tumors", J Surg Oncol, 109, pp.71~74 (2014)
- Jung JH, "Risk factors of lymph node metastasis in patients with gastric neuroendocrine tumor with normal serum gastrin level", Hepatogastroenterology, 62, pp.207~213 (2015)
- Scoazec JY, "Well-differentiated grade 3 digestive neuroendocrine tumors: myth or reality? The PRONET study group", J Clin Oncol, 30(15_Suppl), pp.4129~ (2012)
- Scoazec JY, "Professional practices and diagnostic issues in neuroendocrine tumour pathology : results of a prospective one-year survey among French pathologists(the PRONET study)", Neuroendocrinology, 105, pp.67~76 (2017)
- Pellat A, "Well differentiated grade 3 neuroendocrine tumors of the digestive tract : a narrative review", J Clin Med, 9, pp.1677~ (2020)